Research programme: skin disorders therapy - Starpharma/Stiefel Laboratories
Latest Information Update: 19 Apr 2011
At a glance
- Originator Starpharma; Stiefel Laboratories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Skin disorders
Most Recent Events
- 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline